Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference

WATERTOWN, Mass. ~ Enanta Pharmaceuticals, Inc. announced that data for EDP-323, its oral, once-daily, L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at the 9th European Scientific Working Group on Influenza (ESWI) Influenza Conference. The conference will take place from September 17-20, 2023 at the Palacio de Congresos de Valencia in Valencia, Spain.

The presentation will be given by Kimberly Mills, PharmD and will include results from a Phase 1 study in healthy subjects and correlation with in vitro antiviral activity. It is scheduled to take place on Sunday, September 17th from 8:00 – 9:00 PM CEST / 2:00 – 3:00 PM EDT and Monday, September 18th from 7:30 – 9:00 PM CEST / 1:30 – 3:00 PM EDT. The poster title is "EDP-323, a First-in-Class, Once-Daily, Oral L-Protein Inhibitor for the Treatment of RSV: Results from a Phase 1 Study in Healthy Subjects and Correlation with In Vitro Antiviral Activity" and it can be found in the Poster Hall Exhibit with abstract number 663.

More on Boston Chron
For more information about the ESWI Influenza Conference visit their website.
Filed Under: Business

Show All News | Report Violation


Latest on Boston Chron